Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Roy, Chad J ^a   Ault, Alida ^b   Sivasubramani, Satheesh K ^a   Gorres, J Patrick ^b   Wei, Chih Jen ^b   Andersen, Hanne ^c   Gall, Jason ^d   Roederer, Mario ^b   Rao, Srinivas S ^b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c BIOQUAL INC   (United States)

^d GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD5 VACCINE; ADENOVIRUS VECTOR; HEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS VACCINE; H1N1 VIRUS HEMAGGLUTININ; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; VIRUS ANTIBODY;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; LOWER RESPIRATORY TRACT; LUNG TUBERCULOSIS; MALE; NEBULIZER; NONHUMAN; PARTICLE SIZE; ADENOVIRUS; ANIMAL; BLOOD; CELL STRAIN HEK293; FERRET; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS INFECTION; TIME; VIROLOGY; VIRUS LOAD;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; ANTIBODIES, VIRAL; FERRETS; GENETIC VECTORS; HEK293 CELLS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; NEBULIZERS AND VAPORIZERS; ORTHOMYXOVIRIDAE INFECTIONS; PARTICLE SIZE; TIME FACTORS; TRANSFECTION; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 81355149280     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-153     Document Type: Article

References (38)

1. Brokstad KA, Eriksson JC, Cox RJ, et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 2002, 185(7):878-84. 10.1086/339710, 11920311.
2. Smith DJ, Bot S, Dellamary L, Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003, 21(21-22):2805-12. 10.1016/S0264-410X(03)00224-X, 12798621.
3. Imamura T, Oshitani H. Mucosal immunity against influenza induced by attenuated recombinant Sendai virus. Expert Rev Vaccines 2011, 10(10):1393-5. 10.1586/erv.11.123, 21988304.
4. Park KS, Lee J, Ahn SS, et al. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 2009, 395(2):182-9. 10.1016/j.virol.2009.09.018, 19836045.
5. Svindland SC, Jul-Larsen A, Pathirana R, et al. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses 2011,
6. Quinn K, Quirion MR, Lo CY, Misplon JA, Epstein SL, Chiorini JA. Intranasal Administration of Adeno-associated Virus Type 12 (AAV12) Leads to Transduction of the Nasal Epithelia and Can Initiate Transgene-specific Immune Response. Mol Ther 2011,
7. Smith JH, Brooks P, Johnson S, et al. Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine 2011, 29(14):2568-75. 10.1016/j.vaccine.2011.01.059, 21300100.
8. Song K, Bolton DL, Wei CJ, et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc Natl Acad Sci USA 2010, 107(51):22213-8. 10.1073/pnas.1015536108, 3009829, 21135247.
9. Epstein SL, Lo CY, Misplon JA, et al. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol 1997, 158(3):1222-30.
10. Liang S, Mozdzanowska K, Palladino G, Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994, 152(4):1653-61.
11. Meitin CA, Bender BS, Small PA. Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine 1991, 9(10):751-6. 10.1016/0264-410X(91)90292-E, 1759493.
12. Tamura S, Ito Y, Asanuma H, et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 1992, 149(3):981-8.
13. Armerding D, Rossiter H, Ghazzouli I, Liehl E. Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J Infect Dis 1982, 145(3):320-30. 10.1093/infdis/145.3.320, 6977595.
14. Perrone LA, Ahmad A, Veguilla V, et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009,
15. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001, 75(11):5141-50. 10.1128/JVI.75.11.5141-5150.2001, 114919, 11333895.
16. Nguyen HH, Moldoveanu Z, Novak MJ, et al. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 1999, 254(1):50-60. 10.1006/viro.1998.9521, 9927573.
17. Song SK, Moldoveanu Z, Nguyen HH, et al. Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice. Vaccine 2007, 25(34):6359-66. 10.1016/j.vaccine.2007.06.030, 17640781.
18. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005, 50(9):1161-76.
19. Roth Y, Chapnik JS, Cole P. Feasibility of aerosol vaccination in humans. Ann Otol Rhinol Laryngol 2003, 112(3):264-70.
20. Swayne DE. Avian influenza vaccines and therapies for poultry. Comp Immunol Microbiol Infect Dis 2008,
21. Hubbard RC, Casolaro MA, Mitchell M, et al. Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc Natl Acad Sci USA 1989, 86(2):680-4. 10.1073/pnas.86.2.680, 286537, 2783491.
22. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 1997, 25(3):323-38. 10.1006/biol.1997.0103, 9325001.
23. Rao SS, Kong WP, Wei CJ, et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE 2010, 5(3):e9812. 10.1371/journal.pone.0009812, 2843722, 20352112.
24. Wei CJ, Boyington JC, McTamney PM, et al. Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination. Science 2010,
25. Guy EL, Bosomworth M, Denton M, Conway SP, Brownlee KG, Lee TW. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis. J Cyst Fibros 2010, 9(4):292-5. 10.1016/j.jcf.2010.03.007, 20427245.
26. Hubert D, Leroy S, Nove-Josserand R, et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros 2009, 8(5):332-7. 10.1016/j.jcf.2009.07.001, 19651542.
27. Parkins MD, Elborn JS. Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis. Expert Rev Respir Med 2010, 4(4):435-44. 10.1586/ers.10.48, 20658904.
28. Gall JG, Lizonova A, EttyReddy D, et al. Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes. Mol Biotechnol 2007, 35(3):263-73. 10.1007/BF02686012, 17652790.
29. Aoki K, Barker C, Danthinne X, Imperiale MJ, Nabel GJ. Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol Med 1999, 5(4):224-31. 2230325, 10448644.
30. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58(RR-8):1-52.
31. National Research Council Guide for the care and use of laboratory animals. 1996, Washington (DC), National Academies Press, Ref Type: Generic, National Research Council.
32. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004, 103(1-2):91-5. 10.1016/j.virusres.2004.02.019, 15163495.
33. Wei CJ, Boyington JC, Dai K, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010, 2(24):24ra21. 10.1126/scitranslmed.3000799, 3182573, 20375007.
34. Laddy DJ, Yan J, Kutzler M, et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 2008, 3(6):e2517. 10.1371/journal.pone.0002517, 2429965, 18575608.
35. Schlesinger RB. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J Toxicol Environ Health 1985, 15(2):197-214. 10.1080/15287398509530647, 3892021.
36. Lednicky JA, Hamilton SB, Tuttle RS, Sosna WA, Daniels DE, Swayne DE. Ferrets develop fatal influenza after inhaling small particle aerosols of highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1). Virol J 2010, 7:231. 10.1186/1743-422X-7-231, 2949836, 20843329.
37. Reznik GK. Comparative anatomy, physiology, and function of the upper respiratory tract. Environ Health Perspect 1990, 85:171-6. 1568330, 2384061.
38. Li X, Liu Q, Bi X, et al. An in vitro model to evaluate virus aerosol characteristics using a GFP-expressing adenovirus. J Med Microbiol 2008, 57(Pt 11):1335-9.